Molecular Partners AG (XSWX:MOLN) PB Ratio : 0.61 (As of Apr. 30, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-30), Molecular Partners AG's share price is CHF3.29. Molecular Partners AG's Book Value per Share for the quarter that ended in Dec. 2023 was CHF5.37. Hence, Molecular Partners AG's PB Ratio of today is 0.61.

The historical rank and industry rank for Molecular Partners AG's PB Ratio or its related term are showing as below:

XSWX:MOLN' s PB Ratio Range Over the Past 10 Years
Min: 0.51 Med: 0.87 Max: 8.43
Current: 0.61

During the past 11 years, Molecular Partners AG's highest PB Ratio was 8.43. The lowest was 0.51. And the median was 0.87.

XSWX:MOLN's PB Ratio is ranked better than
89.37% of 1308 companies
in the Biotechnology industry
Industry Median: 2.435 vs XSWX:MOLN: 0.61

During the past 12 months, Molecular Partners AG's average Book Value Per Share Growth Rate was -17.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 13.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 11.70% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -1.10% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Molecular Partners AG was 38.30% per year. The lowest was -27.40% per year. And the median was -9.00% per year.

Back to Basics: PB Ratio

Molecular Partners AG PB Ratio Historical Data

The historical data trend for Molecular Partners AG's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG PB Ratio Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PB Ratio

Get a 7-Day Free Trial

6.99

5.64

5.36

0.94

0.64

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
PB Ratio	Get a 7-Day Free Trial															0.94	0.80	0.86	0.65	0.64

Competitive Comparison of Molecular Partners AG's PB Ratio

For the Biotechnology subindustry, Molecular Partners AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's PB Ratio distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's PB Ratio falls into.

Molecular Partners AG PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Molecular Partners AG's PB Ratio for today is calculated as follows:

PB Ratio	=	Share Price	/	Book Value per Share (Q: Dec. 2023)
	=	3.29	/	5.37
	=	0.61

It can also be calculated from the numbers for the whole company:

PB Ratio

Market Cap

(Total Stockholders Equity

Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Molecular Partners AG (XSWX:MOLN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Molecular Partners AG PB Ratio Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » PB Ratio

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.